The results of the present examples show that anti-EGF antibody levels are significantly lower in patients with ovarian cancer compared to healthy controls. In addition, levels are significantly higher in patients who do not relapse after treatment with panitumumab or chemotherapeutic agents. Levels of anti-EGF antibodies in samples are a well-suited predictor of response to treatment with an inhibitor of EGFR activity. The relapse of cancer or the mortality of the patient as the endpoint of treatment with platinum analogues can be predicted with a high degree of specificity and sensitivity.